Catalyst
Monitor regulatory submissions and approvals for ENSPRYNG in MOGAD, as well as any competitive responses from other companies targeting this indication.
Humanexa recommends Escalate.
Date
June 17, 2026
Phase
N/A
Status
watch
Signal score
9.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.